Research ArticleArticle
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity
Chamaida Plasencia, Eva L. Kneepkens, Gertjan Wolbink, Charlotte L.M. Krieckaert, Samina Turk, Victoria Navarro-Compán, Merel L’Ami, Mike T. Nurmohamed, Irene van der Horst-Bruinsma, Teresa Jurado, Cristina Diego, Gema Bonilla, Alejandro Villalba, Diana Peiteado, Laura Nuño, Desiree van der Kleij, Theo Rispens, Emilio Martín-Mola, Alejandro Balsa and Dora Pascual-Salcedo
The Journal of Rheumatology July 2015, jrheum.141128; DOI: https://doi.org/10.3899/jrheum.141128
Chamaida Plasencia
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Eva L. Kneepkens
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Gertjan Wolbink
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Charlotte L.M. Krieckaert
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Samina Turk
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Victoria Navarro-Compán
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Merel L’Ami
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Mike T. Nurmohamed
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Irene van der Horst-Bruinsma
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Teresa Jurado
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Cristina Diego
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Gema Bonilla
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Alejandro Villalba
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Diana Peiteado
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Laura Nuño
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Desiree van der Kleij
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Theo Rispens
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Emilio Martín-Mola
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Alejandro Balsa
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
Dora Pascual-Salcedo
From the La Paz University Hospital, and the Rheumatology Department, La Paz University Hospital-Idipaz, Madrid, Spain; Sanquin Diagnostic Services; Department of Rheumatology, VU University Medical Centre; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; Jan van Breemen Research Institute|Reade, Amsterdam, the Netherlands. Funded by an unrestricted medical grant from Pfizer. Also supported by the Ministerio de Ciencia e Innovación grant SAF 2009-07100, and by RETICs program RD08/0075 from Instituto Carlos-III (ISCIII). C. Plasencia receives Pfizer grants. G. Wolbink is a speaker for Pfizer. The following authors also have varying affiliations with Pfizer: M.T. Nurmohamed, E. Martin-Mola, A. Balsa, and D. Pascual-Salcedo. C. Plasencia, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; E.L. Kneepkens, MD; G. Wolbink, PhD; C.L. Krieckaert, MD; S. Turk, MD, Jan van Breemen Research Institute|Reade; V. Navarro-Compán, MD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; M. L’Ami, MSc, Jan van Breemen Research Institute|Reade; M.T. Nurmohamed, PhD; I. van der Horst-Bruinsma, PhD, Jan van Breemen Research Institute|Reade and Sanquin Diagnostic Services; T. Jurado, MSC; C. Diego, BSC, La Paz University Hospital; G. Bonilla, MD; A. Villalba, MD; D. Peiteado, MD; L. Nuño, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. van der Kleij, PhD, Sanquin Diagnostic Services; T. Rispens, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam; E. Martín-Mola, PhD; A. Balsa, PhD, Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Rheumatology Department, La Paz University Hospital-Idipaz; D. Pascual-Salcedo, PhD, La Paz University Hospital. Address correspondence to C. Plasencia, University Hospital La Paz, Rheumatology, Castellana 261, Madrid 28046, Spain. E-mail: chamiplasencia@hotmail.com. Accepted for publication May 14, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity
Chamaida Plasencia, Eva L. Kneepkens, Gertjan Wolbink, Charlotte L.M. Krieckaert, Samina Turk, Victoria Navarro-Compán, Merel L’Ami, Mike T. Nurmohamed, Irene van der Horst-Bruinsma, Teresa Jurado, Cristina Diego, Gema Bonilla, Alejandro Villalba, Diana Peiteado, Laura Nuño, Desiree van der Kleij, Theo Rispens, Emilio Martín-Mola, Alejandro Balsa, Dora Pascual-Salcedo
The Journal of Rheumatology Jul 2015, jrheum.141128; DOI: 10.3899/jrheum.141128
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity
Chamaida Plasencia, Eva L. Kneepkens, Gertjan Wolbink, Charlotte L.M. Krieckaert, Samina Turk, Victoria Navarro-Compán, Merel L’Ami, Mike T. Nurmohamed, Irene van der Horst-Bruinsma, Teresa Jurado, Cristina Diego, Gema Bonilla, Alejandro Villalba, Diana Peiteado, Laura Nuño, Desiree van der Kleij, Theo Rispens, Emilio Martín-Mola, Alejandro Balsa, Dora Pascual-Salcedo
The Journal of Rheumatology Jul 2015, jrheum.141128; DOI: 10.3899/jrheum.141128